Business
Top Ranking MedMira Rapid HIV Test Garners Additional Tender Sales in China
Company Sees More Market Development and Product Line Expansion on the Horizon for China...
About this update from Medmira Inc.
[{"type":"text","content":"\n\n\nCompany Sees More Market Development and Product Line Expansion on the\n Horizon for China\n\n\nHALIFAX, July 14, 2014 /CNW/ - MedMira, Inc. (MedMira) (TSXV: MIR) is\n steadily gaining critical market share for its top-ranking rapid HIV test in the highly competitive and crowded Chinese marketplace.  The\n Company, in partnership with Triplex International Biosciences, its\n China-based strategic sales and distribution partner, has shipped\n 100,000 of its rapid HIV tests to multiple provinces in China. MedMira\n has also won follow-on tender business for the supply of 200,000\n additional rapid HIV tests.\n\n\n\"Our growth in China has come primarily through the tender system and we\n continue to build our network of contacts and opportunities in this\n sector.  Approximately 80 percent of rapid HIV tests purchased in China\n each year are procured through tenders, making this a key market sector\n for us,\" said Hermes Chan, CEO of MedMira.  \"The restructuring of\n China's healthcare system and implementation of stricter quality\n standards has positively affected the growth in our market share in\n China. As agencies such as the China CDC demand high performance\n products, there is a trickledown effect happening where these\n evaluations impact provincial tender criteria. It's a win-win for\n MedMira and its products.\"\n\n\nMedMira's rapid HIV test consistently ranks as one of the best in annual\n evaluations conducted by the Chinese Center for Disease Control and\n Prevention (China CDC).  In the 2014 evaluation results from the China\n CDC, MedMira'S rapid HIV test ranked in the top three of all rapid HIV\n tests available in China.  These evaluations are critical support tools\n in MedMira's sales and business activities and help in gaining ground\n in a marketplace that is saturated with imported and domestic rapid\n tests of quality and performance that vary widely.\n\n\nThe Company and its strategic partner will continue to pursue new and\n recurring tender business in various Chinese provinces.  Building on\n this foundation, MedMira plans to expand its brand in China in two\n ways.  First, MedMira is preparing to bring its Multiplo product range\n to China.  The global demand for multiplexed tests is rapidly\n increasing as healthcare providers and public health agencie...